Zurich Cantonal Bank Portfolio holdings
AUM
$40.9B
1-Year Return
22.88%
This Quarter Return
-2.54%
1 Year Return
+22.88%
3 Year Return
+106.76%
5 Year Return
+189.8%
10 Year Return
+428.78%
AUM
$34.8B
AUM Growth
-$269M
(-0.77%)
Cap. Flow
+$1.23B
Cap. Flow
% of AUM
3.54%
Top 10 Holdings %
Top 10 Hldgs %
31.64%
Holding
2,725
New
60
Increased
1,191
Reduced
635
Closed
91
Top Buys
| 1 |
UBS Group
UBS
|
$128M |
| 2 |
Alphabet (Google) Class C
GOOG
|
$99.2M |
| 3 |
Walt Disney
DIS
|
$87.6M |
| 4 |
Adobe
ADBE
|
$81.1M |
| 5 |
Amazon
AMZN
|
$74.8M |
Top Sells
| 1 |
Hubbell
HUBB
|
$60.7M |
| 2 |
Alcon
ALC
|
$39.2M |
| 3 |
Micron Technology
MU
|
$34.8M |
| 4 |
United Rentals
URI
|
$29.2M |
| 5 |
Cadence Design Systems
CDNS
|
$28.9M |
Sector Composition
| 1 | Technology | 27.87% |
| 2 | Financials | 18.07% |
| 3 | Healthcare | 12.65% |
| 4 | Consumer Discretionary | 9.51% |
| 5 | Industrials | 7.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Codexis
CDXS
$218M
| $12.7K | ﹤0.01% |
4,726
+1,729
| +58% | +$4.65K |
|
2502
GlobalFoundries
GFS
$18.5B
| $12.6K | ﹤0.01% |
342
| – | – |
|
2503
argenx
ARGX
$45.9B
| $12.4K | ﹤0.01% |
+21
| New | +$12.4K |
|
2504
Theravance Biopharma
TBPH
$703M
| $12.3K | ﹤0.01% |
1,382
-15,596
| -92% | -$139K |
|
2505
Pliant Therapeutics
PLRX
$114M
| $12.1K | ﹤0.01% |
8,994
+964
| +12% | +$1.3K |
|
|
LENZ
2506
LENZ Therapeutics
LENZ
$1.2B
| $11.8K | ﹤0.01% |
+460
| New | +$11.8K |
|
2507
Inhibrx
INBX
$408M
| $11.5K | ﹤0.01% |
824
+706
| +598% | +$9.88K |
|
2508
Galapagos
GLPG
$2.2B
| $11.4K | ﹤0.01% |
+455
| New | +$11.4K |
|
2509
Omeros
OMER
$284M
| $11.2K | ﹤0.01% |
+1,358
| New | +$11.2K |
|
2510
Amylyx Pharmaceuticals
AMLX
$910M
| $11.2K | ﹤0.01% |
+3,152
| New | +$11.2K |
|
2511
Regenxbio
RGNX
$490M
| $11.1K | ﹤0.01% |
1,553
-15,108
| -91% | -$108K |
|
2512
AstraZeneca
AZN
$253B
| $11K | ﹤0.01% |
150
| – | – |
|
2513
Zevra Therapeutics
ZVRA
$502M
| $11K | ﹤0.01% |
+1,464
| New | +$11K |
|
|
CNTA
2514
Centessa Pharmaceuticals
CNTA
$2.11B
| $10.9K | ﹤0.01% |
755
-1,058
| -58% | -$15.2K |
|
2515
Limoneira
LMNR
$285M
| $10.1K | ﹤0.01% |
571
+84
| +17% | +$1.49K |
|
2516
Alvotech
ALVO
$2.6B
| $9.93K | ﹤0.01% |
+1,027
| New | +$9.93K |
|
2517
Cartesian Therapeutics
RNAC
$277M
| $9.38K | ﹤0.01% |
+712
| New | +$9.38K |
|
2518
AbCellera Biologics
ABCL
$1.26B
| $9.38K | ﹤0.01% |
+4,205
| New | +$9.38K |
|
2519
MaxCyte
MXCT
$150M
| $8.96K | ﹤0.01% |
3,283
+348
| +12% | +$950 |
|
2520
Esperion Therapeutics
ESPR
$540M
| $8.76K | ﹤0.01% |
+6,082
| New | +$8.76K |
|
2521
Monte Rosa Therapeutics
GLUE
$305M
| $8.6K | ﹤0.01% |
+1,853
| New | +$8.6K |
|
2522
ArriVent BioPharma
AVBP
$819M
| $8.45K | ﹤0.01% |
+457
| New | +$8.45K |
|
2523
Design Therapeutics
DSGN
$367M
| $8.36K | ﹤0.01% |
+2,165
| New | +$8.36K |
|
2524
Alpha Teknova
TKNO
$233M
| $8.34K | ﹤0.01% |
+1,607
| New | +$8.34K |
|
|
MESO
2525
Mesoblast
MESO
$1.84B
| $7.9K | ﹤0.01% |
+633
| New | +$7.9K |
|